Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2022 revenue and provided estimates for its 2023 guidance.
Preliminary Fourth Quarter and Full Year 2022 Highlights:
Preliminary unaudited revenue for the fourth quarter of 2022 is expected to be between $107.0 million and $108.0 million, up 12% sequentially and 29% year-over-year (at the midpoint of the range).
Preliminary unaudited revenue for the full year 2022 is expected to be between $382.7 million and $383.7 million, up approximately 38% over the full year 2021 (at the midpoint of the range).
Ended 2022 with over 275 U.S. sales territories.
“Our fourth quarter was successful and highly productive. We executed crisply across all five of our growth drivers and generated robust revenue growth,” said Drew Hykes, CEO of Inari Medical. “We presented important new data from both the CLOUT registry and the U.S. arm of our FLASH registry, the largest prospective thrombectomy trials ever conducted in DVT and PE. We also initiated the full market release of two new products while continuing our work to drive market expansion and uptake of our devices. Looking ahead, we remain fully committed to our mission of better outcomes for our patients while continuing to deliver sustained, premium growth.”
The preliminary unaudited revenue results described in this press release are estimates only and subject to revision, including as a result of completion of customary annual audit procedures, until Inari reports its full financial results for the fourth quarter and full year 2022 in our Annual Report on Form 10-K.
Full Year 2023 Revenue Guidance
Inari is providing financial guidance for full year 2023 revenue of $470 million to $480 million, reflecting growth of approximately 23% to 25% over 2022. Further detail will be provided when Inari reports its financial results for the fourth quarter and full year 2022.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.